Incyte Co. (NASDAQ:INCY) Shares Acquired by DCF Advisers LLC

DCF Advisers LLC lifted its stake in shares of Incyte Co. (NASDAQ:INCY) by 0.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 48,500 shares of the biopharmaceutical company’s stock after purchasing an additional 250 shares during the quarter. Incyte comprises 1.6% of DCF Advisers LLC’s portfolio, making the stock its 21st largest position. DCF Advisers LLC’s holdings in Incyte were worth $3,350,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in INCY. Quintet Private Bank Europe S.A. acquired a new stake in shares of Incyte during the 4th quarter worth approximately $26,000. Global X Japan Co. Ltd. increased its position in Incyte by 144.7% in the 4th quarter. Global X Japan Co. Ltd. now owns 389 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 230 shares during the period. Brooklyn Investment Group acquired a new stake in Incyte in the 3rd quarter valued at approximately $30,000. R Squared Ltd acquired a new stake in Incyte in the 4th quarter valued at approximately $30,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Incyte in the 3rd quarter valued at approximately $33,000. 96.97% of the stock is currently owned by institutional investors and hedge funds.

Incyte Stock Performance

Shares of Incyte stock opened at $60.58 on Friday. The stock has a market cap of $11.72 billion, a PE ratio of 224.38, a price-to-earnings-growth ratio of 0.41 and a beta of 0.76. The business has a fifty day simple moving average of $70.78 and a 200-day simple moving average of $70.13. The company has a quick ratio of 1.94, a current ratio of 1.97 and a debt-to-equity ratio of 0.01. Incyte Co. has a 12 month low of $50.35 and a 12 month high of $83.95.

Incyte (NASDAQ:INCY) last issued its earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.48). Incyte had a return on equity of 0.05% and a net margin of 0.77%. On average, sell-side analysts anticipate that Incyte Co. will post 4.86 EPS for the current fiscal year.

Insider Activity at Incyte

In other Incyte news, EVP Barry P. Flannelly sold 19,807 shares of the business’s stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $67.69, for a total value of $1,340,735.83. Following the completion of the sale, the executive vice president now directly owns 33,567 shares of the company’s stock, valued at $2,272,150.23. The trade was a 37.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Sheila A. Denton sold 599 shares of the firm’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $69.99, for a total transaction of $41,924.01. Following the transaction, the executive vice president now owns 25,848 shares in the company, valued at $1,809,101.52. This represents a 2.26 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 46,827 shares of company stock valued at $3,322,618. Insiders own 17.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on INCY shares. Wells Fargo & Company lifted their price target on Incyte from $68.00 to $70.00 and gave the company an “equal weight” rating in a research report on Thursday, December 19th. Truist Financial lowered their price target on Incyte from $74.00 to $72.00 and set a “hold” rating on the stock in a research report on Tuesday. UBS Group started coverage on Incyte in a research report on Tuesday, December 17th. They set a “neutral” rating and a $77.00 price target on the stock. Guggenheim cut Incyte from a “buy” rating to a “neutral” rating and set a $92.00 price target on the stock. in a research report on Tuesday. Finally, Citigroup lowered their price target on Incyte from $97.00 to $88.00 and set a “buy” rating on the stock in a research report on Tuesday, February 11th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, Incyte currently has an average rating of “Hold” and a consensus price target of $75.13.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.